$3.84 Billion is the total value of Artal Group S.A.'s 108 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -60,697 | -100.0% | -0.01% | – |
| TOCA | Exit | TOCAGEN INC | $0 | – | -100,000 | -100.0% | -0.02% | – |
| SNNAQ | Exit | SIENNA BIOPHARMACEUTICALS IN | $0 | – | -99,000 | -100.0% | -0.03% | – |
| KNSA | Exit | KINIKSA PHARMACEUTICALS LTD | $0 | – | -100,000 | -100.0% | -0.04% | – |
| IDRA | Exit | IDERA PHARMACEUTICALS INC | $0 | – | -2,750,000 | -100.0% | -0.08% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORPcall | $0 | – | -250,000 | -100.0% | -0.08% | – |
| WVE | Exit | WAVE LIFE SCIENCES LTD | $0 | – | -100,000 | -100.0% | -0.08% | – |
| GLYC | Exit | GLYCOMIMETICS INC | $0 | – | -250,000 | -100.0% | -0.09% | – |
| AGIO | Exit | AGIOS PHARMACEUTICALS INCcall | $0 | – | -50,000 | -100.0% | -0.09% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INCcall | $0 | – | -100,000 | -100.0% | -0.10% | – |
| XLRN | Exit | ACCELERON PHARMA INCcall | $0 | – | -100,000 | -100.0% | -0.10% | – |
| VTL | Exit | VITAL THERAPIES INC | $0 | – | -1,000,000 | -100.0% | -0.15% | – |
| BLUE | Exit | BLUEBIRD BIO INCcall | $0 | – | -50,000 | -100.0% | -0.17% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -200,000 | -100.0% | -0.19% | – |
| EXEL | Exit | EXELIXIS INCcall | $0 | – | -500,000 | -100.0% | -0.23% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORPcall | $0 | – | -200,000 | -100.0% | -0.27% | – |
| IBB | Exit | ISHARES TRcall | $0 | – | -450,000 | -100.0% | -1.05% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-05-17 |
| 4 | 2024-05-14 |
| 13F-HR | 2024-05-13 |
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.